Rgenta Therapeutics is a company developing RNA-targeting medicines focused on oncology and neurological disorders. Its platform mines genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.